The information provided on this page is for reference only. Please refer to the latest information published by the partner company.
Founded in December 2018, BP InnoMed Limited is a spin-off company from the Hong Kong Baptist University, which has a vision to improve life of cancer patients by making innovative high-quality medicine and healthcare product safe and effective.
The company was established with an exceptionally strong in-house scientific team and world-renown external consultants with chemical biology, medicinal chemistry and synthetic organic chemistry background. We are dedicated to developing a wide range of pioneering medical products, including theranostics probes, intelligent molecular sensors, and certain pro-drugs with diverse set of properties for medical diagnostics and cancer therapy or rehabilitation.
Our current project focuses on the development and the commercialization of the “Theranostics inhibitors for eradicating Epstein-Barr Virus (EBV) associated cancer”, for example, nasopharynx cancer (NPC), a common cancer especially in the southern part of China cancer.
Our current project focuses on developing and commercializing the “Theranostics inhibitors for eradicating Epstein-Barr Virus (EBV) associated cancer”, including Nasopharyngeal Carcinoma, a cancer intimately related with EBV. To our knowledge, there is currently no FDA (or equivalent)-approved EBV-specific targeted therapy in the pharmaceutical industry.
BP InnoMed Limited had successfully established a probe – L2P4 – targeting EBNA1 (the only viral protein expressed in all EBV-associated cancer cells). Our probe can specifically inhibit EBV-associated tumour growth and in addition emit fluorescent signal when bound to EBNA1. The studies on our discovery show that 0.2 mg/kg of L2P4 is able to inhibit over 90% EBV-tumour growth in mice. We have also modified L2P4 by incorporating a zinc chelator to make a new EBNA1 inhibitor ZRL5P4, which can reactivate the EBV lytic induction.
Leading by our experienced professional team and under the protection of our intellectual properties, we aim to develop such EBV inhibitor to obtain IND approval and go through clinical trial 1.